LOGIN  |  REGISTER
Cue Biopharma

Encompass Health announces date of 2024 first quarter earnings call

April 10, 2024 | Last Trade: US$82.88 0.50 -0.60

BIRMINGHAM, Ala., April 10, 2024 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced it will report results for its first quarter ended March 31, 2024, after the market closes Wednesday, April 24, 2024. The Company will host an investor conference call at 10 a.m. ET on April 25, 2024, to discuss its results.

The conference call may be accessed by dialing 800-579-2543 and giving the conference ID EHCQ124. International callers should dial 785-424-1699 and give the same conference ID. Please call approximately 10 minutes before the start of the call to ensure you are connected.

A live webcast of the conference call and an online replay of the conference call can be found on the Company's investor website at https://investor.encompasshealth.com.

About Encompass Health

Encompass Health (NYSE: EHC) is the largest owner and operator of rehabilitation hospitals in the United States. With a national footprint that includes 160 hospitals in 37 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's World's Most Admired Companies and Modern Healthcare's Best Places to Work in Healthcare. For more information, visit encompasshealth.com, or follow us on our newsroom, Twitter, Instagram and Facebook.

Media contact:
Kennedi Spurling | 205-970-5912
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Relations contact:
Mark Miller | 205-970-5860
This email address is being protected from spambots. You need JavaScript enabled to view it.

Surmodics

Stock Quote

Featured Stock

Surmodics

Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB